| CINF | Sunday, August 19, 2007 | ||
2:00 PM-5:40 PM BCEC -- 252 A, Oral | |||
Drug Reprofiling | |||
| Organizers: | Alexander Tropsha Christopher A. Lipinski | ||
| 2:00 PM | 14 | MLR-1023: A drug candidate for type II diabetes with a novel molecular target discovered by using an in vivo drug repositioning approach Michael S. Saporito, Christopher A. Lipinski, Alexander Ochman, Dana Koemer, Jan Batten, Andrew Reaume | |
| 2:25 PM | 15 | Construction of a virtual library of endocrine disruptors for in silico target fishing Christian Laggner, Lyubomir G. Nashev, Daniela Schuster, Thierry Langer, Alex Odermatt | |
| 2:50 PM | 16 | "Emergency discovery"; of novel antimicrobials among known drugs in response to new and reemerging infectious threats Artem Cherkasov | |
| 3:15 PM | 17 | Effective and rapid bioactivity profiling using pharmacophore-based parallel screening Theodora M. Steindl, Daniela Schuster, Johannes Kirchmair, Remy Hoffmann, Christian Laggner, Gerhard Wolber, Thierry Langer | |
| 3:40 PM | Intermission | ||
| 4:00 PM | 18 | Knowledge-based prediction for alternate indications and targets for known drugs A. W. Edith Chan, John P Overington | |
| 4:25 PM | 19 | Synergistic advantages of drug reprofiling and clinical trial offshoring in India J. Maki | |
| 4:50 PM | 20 | Drug reprofiling platform as a risk leverage strategy in drug discovery Akinori Mochizuki | |
| 5:15 PM | 21 | Taking advantage of therapeutic switching: Commercialization in a world of generic substitution David Cavalla | |
Previous Session -- Drug Reprofiling
Symposium Grid -- Division of Chemical Information -- Session Listing
The 234th ACS National Meeting, Boston, MA, August 19-23, 2007